BioVaxys Reports Positive Phase 2 Data for Maveropepimut + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab ) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S in Women with Hormone Receptor Positive/HER2 Negative Stage II-III Breast Cancer
Cartier Extends Mineralized System 4 km East of Main; Cuts 23.2 g/t Au over 1.0 m at Nordeau ; Expands High-Grade Gold Near Surface at East Nordeau Zone
NevGold Drills 8.51 g/t Oxide AuEq Over 10.6 Meters Within 2.32 g/t Oxide AuEq Over 86.8 Meters ; Discovers High-Grade Oxide Gold-Antimony "Armory Fault" Structure At Bullet Zone
